Risk factors for catheter‐related thrombosis (CRT) in cancer patients: a patient‐level data (IPD) meta‐analysis of clinical trials and prospective studies

Background: Knowledge of independent, baseline risk factors for catheter‐related thrombosis (CRT) may help select adult cancer patients who are at high risk to receive thromboprophylaxis. Objectives: We conducted a meta‐analysis of individual patient‐level data to identify these baseline risk factors. Patients/Methods: MEDLINE, EMBASE, CINAHL, CENTRAL, DARE and the Grey literature databases were searched in all languages from 1995 to 2008. Prospective studies and randomized controlled trials (RCTs) were eligible. Studies were included if original patient‐level data were provided by the investigators and if CRT was objectively confirmed with valid imaging. Multivariate logistic regression analysis of 17 prespecified baseline characteristics was conducted. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. Results: A total sample of 5636 subjects from five RCTs and seven prospective studies was included in the analysis. Among these subjects, 425 CRT events were observed. In multivariate logistic regression, the use of implanted ports as compared with peripherally implanted central venous catheters (PICCs), decreased CRT risk (OR, 0.43; 95% CI, 0.23–0.80), whereas past history of deep vein thrombosis (DVT) (OR, 2.03; 95% CI, 1.05–3.92), subclavian venipuncture insertion technique (OR, 2.16; 95% CI, 1.07–4.34) and improper catheter tip location (OR, 1.92; 95% CI, 1.22–3.02), increased CRT risk. Conclusions: CRT risk is increased with use of PICCs, previous history of DVT, subclavian venipuncture insertion technique and improper positioning of the catheter tip. These factors may be useful for risk stratifying patients to select those for thromboprophylaxis. Prospective studies are needed to validate these findings.

[1]  U. Hoffmann,et al.  [Upper extremity deep venous thrombosis]. , 2012, Deutsche medizinische Wochenschrift.

[2]  F. Bourgeois,et al.  Peripherally Inserted Central Catheters , 2011, Pediatric emergency care.

[3]  M. De Cicco,et al.  Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Khorana,et al.  Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Clifford W Colwell,et al.  Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .

[6]  B. Barlogie,et al.  Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma , 2008, Leukemia.

[7]  C. Freytes Thromboembolic complications related to central venous access catheters in cancer patients. , 2007, Seminars in thrombosis and hemostasis.

[8]  C. Porta,et al.  Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. De Cicco,et al.  Short-term acenocumarine (A) or dalteparine (D) for the prevention of central venous catheter-related thrombosis (CVCrT) in cancer patients. A randomized controlled study based on serial venographies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Levine,et al.  Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Steger,et al.  Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  L. Castagna,et al.  High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  T. Othman,et al.  Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients , 2005, Bone Marrow Transplantation.

[14]  D. Anderson,et al.  Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Armando Santoro,et al.  Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Kerr,et al.  WARP - A multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs) , 2005 .

[17]  T. Barbui,et al.  Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study , 2005, British journal of haematology.

[18]  R. Rosovsky,et al.  Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management. , 2005, Hematology/oncology clinics of North America.

[19]  S. Povoski Long-term venous access , 2005 .

[20]  G. Severi,et al.  Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  F. Rosendaal,et al.  The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. , 2004, Haematologica.

[22]  Michael K Gould,et al.  Preventing complications of central venous catheterization. , 2003, The New England journal of medicine.

[23]  G. Lambertenghi-Deliliers,et al.  Central Venous Catheter-related Complications in Patients with Hematological Malignancies: A Retrospective Analysis of Risk Factors and Prophylactic Measures , 2003, Leukemia & lymphoma.

[24]  S. Laporte,et al.  Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. , 2003, Haematologica.

[25]  K. Sepkowitz,et al.  Complication rates among cancer patients with peripherally inserted central catheters. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Solomon,et al.  Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin. , 2001, European journal of cancer.

[27]  F. Orsi,et al.  A randomized, prospective trial of central venous ports connected to standard open‐ended or Groshong catheters in adult oncology patients , 2001, Cancer.

[28]  KyungMann Kim,et al.  Central venous device‐related infection and thrombosis in patients treated with moderate dose continuous‐infusion interleukin‐2 , 2001, Cancer.

[29]  J. Heit,et al.  Prevention of venous thromboembolism. , 2001, Clinics in geriatric medicine.

[30]  P. Massoure,et al.  [Upper extremity deep venous thrombosis. 40 hospitalized patients]. , 2000, Journal des maladies vasculaires.

[31]  S. Povoski A Prospective Analysis of the Cephalic Vein Cutdown Approach for Chronic Indwelling Central Venous Access in 100 Consecutive Cancer Patients , 2000, Annals of Surgical Oncology.

[32]  J. Todd Peripherally inserted central catheters. , 1998, Professional nurse.

[33]  P Prandoni,et al.  Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. , 1997, Archives of internal medicine.

[34]  R. Rosell,et al.  Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin) , 1996, Thrombosis and Haemostasis.

[35]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[36]  P. Benotti,et al.  Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.

[37]  E. Larson,et al.  Hickman Catheter Infections in Patients With Malignancies , 1984, Medicine.

[38]  J. Lokich,et al.  Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy , 1983, Cancer.